Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 14/20 | 1.00 |
| ▸ | CA2 | P00918 | 7/20 | 1.00 |
| ▸ | CA9 | Q16790 | 6/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13318875 | 1.00 | STS (1.00) | STSCA2CA9CA1ABCC4 | |
| SCHEMBL14513805 | 1.00 | STS (1.00) | STSCA2CA9CA1ABCC4 | |
| SCHEMBL446846 | 1.00 | STS (1.00) | STSCA2CA9CA1ABCC4 | |
| SCHEMBL29551370 | 1.00 | STS (1.00) | STSCA2CA9CA1ABCC4 | |
| SCHEMBL14549386 | 1.00 | STS (1.00) | STSCA2CA9CA1ABCC4 | |
| SCHEMBL13318877 | 0.95 | STS (0.91) | STSCA2CA9CA1ABCC4 | |
| SCHEMBL14395445 | 0.91 | STS (0.83) | STSCA2CA9CA1ABCC4 | |
| SCHEMBL1237204 | 0.90 | STS (0.81) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL14070736 | 0.89 | STS (0.80) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL4212438 | 0.89 | STS (0.80) | STSCA2CA9CA1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2484351-B1 | Use of steroid sulfatase inhibitors for the treatment of preterm labor | PREGLEM SA (CH) | 2016-02-24 | — | — | EP | disclosed |
| EP-2117530-B1 | COMPOSITION COMPRISING 2DG AND STX140 FOR THE TREATMENT OF CANCER | STERIX LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| EP-2484351-A1 | Use of steroid sulfatase inhibitors for the treatment of preterm labor | PregLem S.A. (CH) | 2012-08-08 | — | — | EP | disclosed |
| EP-2323646-B1 | USE OF STEROID SULFATASE INHIBITORS FOR THE TREATMENT OF PRETERM LABOR | PREGLEM SA (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110118224-A1 | USE OF STEROID SULFATASE INHIBITORS FOR THE TREATMENT OF PRETERM LABOR | PREGLEM SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-20110118224-A1 | USE OF STEROID SULFATASE INHIBITORS FOR THE TREATMENT OF PRETERM LABOR | PREGLEM SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-7893284-B2 | Oestrogen derivatives as inhibitors of steroid sulphatase | STERIX LIMITED (GB) | 2011-02-22 | — | — | US | disclosed |
| US-7893284-B2 | Oestrogen derivatives as inhibitors of steroid sulphatase | STERIX LIMITED (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20100204146-A1 | Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women | PREGLEM S.A. (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204146-A1 | Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women | PREGLEM S.A. (CH) | 2010-08-12 | — | — | US | disclosed |
| WO-2010013187-A1 | USE OF STEROID SULFATASE INHIBITORS FOR THE TREATMENT OF PRETERM LABOR | PREGLEM SA (CH) | 2010-02-04 | — | — | WO | disclosed |
| EP-2149371-A1 | Use of steroid sulfatase inhibitors for the treatment of preterm labor | PregLem S.A. (CH) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009037539-A2 | TREATMENT OF OESTROGEN DEPENDANT CONDITIONS IN PRE-MENOPAUSAL WOMEN | PREGLEM S.A. (CH) | 2009-03-26 | — | — | WO | disclosed |
| EP-1418921-B1 | ANTI-TUMOUR 2-ALKOXYESTRADIOL SULFAMATES | STERIX LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20070225256-A1 | COMPOUND | STERIX LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
| US-20070225256-A1 | COMPOUND | STERIX LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204146-A1 | Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women | STS, CYP19A1, SHBG | STS 1/4885CA2 1674/4885CA9 1766/4885 |
| US-20110118224-A1 | USE OF STEROID SULFATASE INHIBITORS FOR THE TREATMENT OF PRETERM LABOR | STS, SULT1E1, SULT1A1 | STS 1/4885CA2 458/4885CA9 2203/4885 |
| US-20070225256-A1 | COMPOUND | NR5A1, SRD5A1, SRD5A2 | STS 47/4885CA2 1299/4885CA9 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.